On Tuesday, Revolution Medicines Inc (NASDAQ: RVMD) was 4.50% up from the session before settling in for the closing price of $35.67. A 52-week range for RVMD has been $29.17 – $62.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -27.80%. When this article was written, the company’s average yearly earnings per share was at -48.34%. With a float of $162.02 million, this company’s outstanding shares have now reached $186.90 million.
Revolution Medicines Inc (RVMD) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Revolution Medicines Inc stocks. The insider ownership of Revolution Medicines Inc is 13.33%, while institutional ownership is 91.89%. The most recent insider transaction that took place on Jun 20 ’25, was worth 75,736. In this transaction General Counsel of this company sold 1,912 shares at a rate of $39.61, taking the stock ownership to the 54,093 shares. Before that another transaction happened on Jun 20 ’25, when Company’s Officer proposed sale 1,912 for $39.93, making the entire transaction worth $76,346.
Revolution Medicines Inc (RVMD) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.94 earnings per share (EPS) during the time that was less than consensus figure (set at -0.88) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -48.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.28% during the next five years compared to -27.80% drop over the previous five years of trading.
Revolution Medicines Inc (NASDAQ: RVMD) Trading Performance Indicators
You can see what Revolution Medicines Inc (RVMD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 11.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.50, a number that is poised to hit -1.41 in the next quarter and is forecasted to reach -5.73 in one year’s time.
Technical Analysis of Revolution Medicines Inc (RVMD)
Looking closely at Revolution Medicines Inc (NASDAQ: RVMD), its last 5-days average volume was 1.64 million, which is a drop from its year-to-date volume of 1.87 million. As of the previous 9 days, the stock’s Stochastic %D was 59.38%.
During the past 100 days, Revolution Medicines Inc’s (RVMD) raw stochastic average was set at 55.90%, which indicates a significant decrease from 83.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.32 in the past 14 days, which was lower than the 1.59 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.42, while its 200-day Moving Average is $41.21. However, in the short run, Revolution Medicines Inc’s stock first resistance to watch stands at $37.91. Second resistance stands at $38.55. The third major resistance level sits at $39.69. If the price goes on to break the first support level at $36.13, it is likely to go to the next support level at $34.98. Should the price break the second support level, the third support level stands at $34.35.
Revolution Medicines Inc (NASDAQ: RVMD) Key Stats
There are 186,933K outstanding shares of the company, which has a market capitalization of 6.97 billion. As of now, sales total 0 K while income totals -600,090 K. Its latest quarter income was 0 K while its last quarter net income were -247,790 K.
